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Abstract
Boesenbergia pandurata and its major active ingredient, panduratin A (PAN), exhibit antibacterial, anti-oxidant, antiinﬂammatory, and anti-obesity effects. We explored the time course of the plasma and tissue (in the major organs, gums
and skin) concentrations of PAN after oral administration of a B. pandurata extract to rats. Model-dependent analysis
was used to quantify the skin distribution of PAN after systemic exposure. The PAN level peaked at 1.12 ± 0.22 mg/mL
after 3 h, and then biexponentially decayed with a terminal half-life of 9 h. The mean clearance (Cl/F) was 2.33 ± 0.68 L/h/
kg. The PAN levels in organs were in the following order (highest ﬁrst): skin, lung, heart, gum, liver, spleen, kidney, and
brain. For the ﬁrst time, the time course of PAN levels in plasma and organs was investigated after oral administration of
a BPE. This study helps to explain the pharmacological activities of PAN in the skin and gums. The pharmacokinetic
model provided data in the plasma and skin concentrations of PAN, which are of fundamental importance to evaluate its
efﬁcacy.
Keywords: BPE, Panduratin A, Pharmacokinetic modeling, Plasma, Skin

1. Introduction

B

oesenbergia pandurata Roxb. is a tropical plant of
the Zingiberaceae family commonly referred to
as ﬁngerroot. Panduratin A (PAN; Fig. 1), a chalcone, is the major bioactive agent of B. pandurata [1]
and has antibacterial, anti-inﬂammatory, antioxidant, and anti-obesity effects [2e4]. Previous
studies of the anti-inﬂammatory effects of PAN used
lipopolysaccharide (LPS)-stimulated RAW264.7 cells
[5,6]. Both B. pandurata extract (BPE) and PAN
exhibited anti-periodontitis activity in LPS-treated
animal models [7,8]. In 2012, BPE was approved as a
health/functional food by the Ministry of Food and
Drug Safety of Korea (No. 2012e36), and was

indicated for use as a dietary supplement and in
skin moisturizers and products protecting the skin
against ultraviolet (UV) light exposure [9e12].
In previous in vivo work, BPE was administered at
50 and 200 mg/kg to investigate its anti-inﬂammatory effects in a lipopolysaccharide-induced periodontitis and alveolar bone loss rat model [8]. BPE
signiﬁcantly increased the mRNA and protein
expression levels of nuclear factor kappa B (NF-kB),
interleukin-1b, matrix metalloproteinase (MMP)-2,
and MMP-8. BPE also exerted inhibitory effects on
the expression of nuclear factor of activated T cells,
cytoplasmic 1, c-Fos, and osteoclastogenesis-related
enzymes, including cathepsin K and tartrate-resistant acid phosphatase (TRAP). BPE upregulated
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Fig. 1. Chemical structure of pandurantin A (left) and pharmacokinetic model (right) of the time courses of plasma (dotted box) and skin panduratin A
levels following oral administration of 200 mg/kg BPE to rats; b, bolus administration into the stomach; a, depot compartment; c, central; p, peripheral; s, skin; Ka, absorption rate constant; t, delay parameter; Kel, elimination rate constant; Kij, ﬁrst-order rate constant from compartment i to j;
Vi, volume of compartment i.

osteoblastogenesis-associated markers, such as
collagen type I and TRAP, and increased the ratio of
osteoprotegerin to receptor activator of NF-kB
ligand.
In a high-fat-induced obesity mouse model, BPE
was given at 200 mg/kg for 8 weeks [13]. BPE
reduced body weight in the absence of alterations in
food intake and serum levels of total cholesterol,
low-density lipoprotein cholesterol, and triglycerides, which might be attributed to activation
of AMP-activated protein kinase signalling and
regulation of the expression of lipid metabolismrelated proteins.
Although the pharmacological activities of both
plant extracts and PAN have been intensively
studied, the pharmacokinetics of PAN in rats have
been reported only by our group [14]. The mean
terminal phase half-life and clearance were 3.6 h
and 3.7 L/h/kg, respectively, following oral administration. Systemic exposure levels (including tissue
distribution) are required when studying the pharmacodynamic actions of the active ingredients of
plants.
In this work, we explored the time courses of
plasma and organ (lung, heart, spleen, liver, kidney,
and brain, including skin and gum) PAN levels
following oral administration of BPE at 200 mg/kg in
rats. The content of PAN in BPE was 8%, and the
BPE dose (200 mg/kg) was equivalent to 16 mg/kg of
PAN [8]; 50 and 100 mg/kg of BPE were also given to
investigate the dose-dependency of systemic exposure to PAN. The deposition of PAN in the skin was
the main focus. The time proﬁles of plasma and skin
PAN concentrations were modelled using a
compartmental modelling approach, which was
applied to simulate PAN levels in skin and plasma
after multiple doses of BPE.

2. Methods
2.1. Materials
The dried rhizomes of B. pandurata were collected
in Jakarta, Indonesia, and identiﬁed by Dr. Nam-In
Baek (Department of Oriental Medicinal Materials
and Processing, Kyunghee University, Yongin,
Korea). The BPE was obtained by following a standard operating procedure [8]. Brieﬂy, dried rhizomes
of B. pandurata (Roxb.) were ground and extracted
into 95% (v/v) ethanol for 3 days at room temperature. The ﬁltrate was evaporated and the PAN content measured. The chromatogram and mass spectra
of pandurate A are shown in Supplement 1. Ethanol
was obtained from Duksan Chemicals (Kyunggi-do,
South Korea). Flufenamic acid and acetonitrile were
purchased from SigmaeAldrich (St. Louis, MO,
USA); PAN (purity, 97.5%) was obtained from Natural Remedies Private Ltd. (Karnataka, India).
2.2. Animal study
We used 30 9-week-old male SpragueeDawley
rats (280e300 g). The animal room was maintained
at a temperature of 23 ± 3  C, with relative humidity
of 50 ± 10% (10e20 air changes/h), and light intensity of 300 Lux under a 12-h/12-h light/dark
cycle. This study was approved by the Institutional
Animal Care and Use Committee (IACUC) at
Chung-Ang University (approval no. 201900025). All
animals were cared for in accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
The rats were randomized to two groups (plasma
and tissue groups) including 5 and 25 animals,
respectively. BPE (200 mg/kg) was orally administered in corn oil (1 mL/kg). Heparinized blood
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samples (100 mL) were prepared at 0.5, 1, 1.5, 2, 2.5, 3,
4, 5, 6, 8, 12 and 24 h after extract administration;
blood was collected via the subclavian vein. After
centrifugation for 10 min at 17,000 rpm, 30-mL
plasma samples were stored at 70  C prior to
analysis [14]. The tissue group rats were euthanized
with isoﬂurane, and as much blood as possible was
collected from the abdominal before harvesting the
organs. Heart, lungs, liver, spleen, kidney, brain,
gums, and skin were collected at 1, 3, 6, 12 and 24 h
in ﬁve subgroups of ﬁve rats each. The tissues were
homogenized in a three-fold excess of phosphate
buffer solution (0.1 M, pH 7.4), and an aliquot of 30mL was analyzed.
An additional 10 rats were evenly divided into two
groups to explore the dose-dependency of systemic
exposure to PAN following oral administration of
BPE; 50 and 100 mg/kg of BPE were given, and
plasma PAN concentrations were monitored as
described above.
2.3. Measurement of panduratin A in extract,
plasma, and tissues by LC-MS/MS
PAN concentrations were determined by highperformance liquid chromatography/tandem mass
spectrometry (LC-MS/MS), as previously described
[14]. PAN content in the extract was determined as
follows: the extract powder was initially dissolved in
dimethylsulfoxide at 1 mg/mL, ﬁltered, and further
diluted with methanol; the calibration standard
curve of PAN in methanol was analysed to quantify
the PAN concentration in the diluted solution.
PAN and ﬂufenamic acid (internal standard, IS)
were dissolved in methanol to concentrations of
1.0 mg/mL. Then, PAN solutions were serially
diluted with methanol, and 10 mL of diluted solution
was added to 90 mL of drug-free plasma and tissue
homogenates to obtain calibration standard plasma
samples with concentrations of 5, 10, 50, 200, 500,
1,000, and 3,000 ng/mL. Three hundred microliters
of acetonitrile, including the IS (10 ng/mL), were
added to the calibration standards; the mixture was
then vigorously vortexed for 10 s and centrifuged for
10 min at 17,000 rpm. Five microliters of the supernatant were injected into an API 4000 LC/MS/MS
system (ABSCIEX, Framingham, MA, USA). Using
linear regression, calibration graphs were derived
from the ratio between the area under the PAN peak
and the IS peak.
The compounds were separated on a reverse
phase column (Atlantis T3; internal diameter,
50  2.1 mm; particle size, 3 mm; Waters, Milford,
MA, USA) at 30  C. The mobile phase was distilled
water with 0.1% (v/v) formic acid and acetonitrile

(4:6, v/v). Elution was performed over 5 min using
an HP 1260 series pump (Agilent, Wilmington, DE,
USA) at a rate of 0.2 mL/min. The turbo ion spray
interface in the LC-MS/MS system was operated at
4500 V at 450  C. The ion transitions of the precursor
to the product ion were deprotonated ions [MH]
at m/z 405.2 / 165.9 (declustering potential,
110 eV; collision energy, 36 eV) for panduratin A
and 280.1 / 236.0 (declustering potential, 75 eV;
collision energy,24 eV) for ﬂufenamic acid [14].
Quantiﬁcation was performed by selective reaction
monitoring of deprotonated precursor ions and
related product ions using the ratio of the area
under the peak for each solution. All analytical data
were processed using Analyst software (ver. 1.5.2;
Applied Biosystems, Foster City, CA, USA).
Ninety microliters of the IS solution was added to
30 mL of a biological sample, followed by application
of the same procedure described above for the
calibration standards. Recovery was calculated by
comparing the mean peak areas of plasma samples
(low, 30 ng/mL; intermediate, 500 ng/mL) spiked
before protein precipitation to those spiked after
deproteination with acetonitrile. The matrix effect
was evaluated based on the percentile of the mean
peak areas of plasma samples spiked after pretreatment with methanol.
2.4. Model-independent analysis
The pharmacokinetic parameters of PAN,
including the maximum concentration (Cmax) and
time to Cmax (Tmax), were calculated from the time
course of the plasma concentration. The elimination
rate constant (k) was estimated by linear regression
of the log-transformed plasma PAN concentration
in the terminal phase. The trapezoidal rule was
used to obtain the area under the plasma
concentrationetime curve (AUCt). The AUCinf was
calculated by adding Clast/k to AUCt, and the
clearance was estimated as the dose/AUCinf. Data
are represented as means with standard deviations.
2.5. Model-dependent analysis
We used a sequential approach to optimize the
models of plasma and skin PAN concentrations
over time; the two-compartment model included
ﬁrst-order elimination and absorption, and a delay
term (t) (Fig. 1 right, dotted line) [15]. In the next
step, a compartment was added to model the skin
PAN concentration over time. All parameters
except those related to absorption (Ka and t) were
estimated.

The differential equations describing the changes
in PAN level in each compartment are as follows:


dx1
¼ Ka : x2  Kel þ Kcp þ Kcs : x1 þ Kpc : x3 þ Ksc :x4
dt
ð1Þ
dx2
¼  Ka :x2
dt

ð2Þ

estimates were evaluated based on the coefﬁcients
of variation (CVs) of the estimates, the parameter
correlation matrix, the sum of squares of the residuals, and visual examination of the residual distributions. In the ﬁrst step, individual datasets were
independently ﬁtted, and mean and variance data
were obtained for each pharmacokinetic parameter.

3. Results

dx3
¼ Kcp :x1  Kpc :x3
dt

ð3Þ

dx4
¼ Kcs :x1  Ksc :x4
ð4Þ
dt
Equations (1)e(4) were solved numerically, and
ﬁtted to the data via maximum likelihood estimation
using the ADAPT 5 software package (Biomedical
Simulations Resource, Los Angeles, CA, USA) and
the following error model:
b i Þ ¼ Cðti Þ þ ei
Cðt
var½ei ðtÞ ¼ ðs0 þ s1 ,Cðti ÞÞ

679

ð5Þ
2

ð6Þ

where C(t) is the measured concentration, and
b s Þ ¼ x4 ðtÞ=Vs are the model
b c Þ ¼ x1 ðtÞ=Vc and Cðt
Cðt
predictions of the plasma and skin PAN concentrations, respectively.
The goodness-of-ﬁt of the model was initially
evaluated by visual inspection of the overlap between the measured concentrations and predicted
values. Several models were compared using the
likelihood ratio test [16]. A p-value <0.05 was
considered signiﬁcant. The simplest model that
adequately explained the data was selected; this
model followed the parsimony principle. The
goodness-of-ﬁt and quality of the parameter

3.1. Measurement of panduratin A in extract,
plasma, and tissues
There was no endogenous interference in the
elution times of PAN or IS in tissue homogenates.
The mean calibration curve of PAN in plasma was
y ¼ 0.030x þ 0.342 (r2, 0.998); a good linearity
was also represented in all tissues, and the representative mean calibration curve in the liver was
y ¼ 0.034x þ 0.511 (r2, 0.999). The mean recovery and
matrix effect using the present protein precipitation
method with acetonitrile were 86 ± 5% and 85 ± 6%
for plasma, and 89 ± 4% and 82 ± 7% for the liver,
respectively.
3.2. Time course of plasma and organ PAN levels
following oral administration of a BPE
The time course of the plasma PAN concentration
is shown in Fig. 2A. PAN was absorbed relatively
slowly, with the highest plasma concentration
(1.12 ± 0.22 mg/mL) seen 3 h after administration.
The concentration rapidly decreased to 380 ± 78 ng/
mL by 6 h, and decayed more gradually thereafter
(terminal half-life ¼ 8.5 ± 1.3 h). The mean AUCinf
and clearance (Cl/F) were 7.84 ± 1.54 mg h/mL and
2.33 ± 0.68 L/h/kg, respectively.

Fig. 2. Panel A: time course of plasma PAN concentrations after oral administration of 200 mg/kg BPE (16 mg/kg as panduratin A) to rats
(mean ± s.d., n ¼ 5); the insert is a semi-logarithmic graph. Panel B: AUCinf (area under the plasma PAN concentrationetime curve) vs. dose of BPE
(mean ± s.d., n ¼ 5); the dotted line indicates the result of regression.
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The AUCinf of PAN vs. the dose of BPE is shown in
Fig. 2B. The systemic exposure to PAN was proportional to the dose of BPE in the range of
50e200 mg/kg, with good linearity (r2, 0.997). The
terminal half-lives of PAN at 50 and 100 mg/kg BPE
were 8.2 ± 1.8 and 9.2 ± 2.1 h, respectively, indicating that there was no saturable metabolism or
excretion of PAN in the dosing range of BPE.
Figure 3 illustrates the time proﬁles of PAN concentrations in organs (3A: lung, heart, skin, and
spleen; 3B: liver, kidney, gums, and brain). The
changes in lung and heart PAN levels were similar
to that seen in plasma; the gum, liver, spleen, kidney, and brain levels were lower than those in the
lung and heart. Interestingly, the maximum skin
concentration was recorded 6 h after those of the
other organs and slowly decreased thereafter. The
AUCt values after 24 h were in the following order
(highest ﬁrst): skin, lung, heart, gums, liver, spleen,
kidney, and brain (Table 1).
3.3. Pharmacokinetic modeling of plasma and skin
PAN levels following oral administration of a BPE
The plasma PAN concentrationetime proﬁle was
derived using a two-compartment model including
ﬁrst-order absorption and elimination. As shown in
the left panel of Fig. 4, the modeled and measured
values around the peak concentration were not
similar when the concentration at time 0 (0 ng/mL)
was included. The plasma PAN concentration
increased much more slowly over the ﬁrst 30 min
than over the next 30 min, and there was a clear
latency between PAN administration and its

appearance in the circulation. Therefore, a delay
term (t) was incorporated to shift the curve to the
right. The delay was about 0.36 h and the model ﬁt
improved signiﬁcantly ( p < 0.01, Fig. 4, middle).
In the second step, an additional compartment
was linked to the central compartment (the skin)
(Fig. 1 right). All modeled parameters, except Ka and
t, showed a good ﬁt with the time course of the skin
PAN level (Fig. 4 right). The ﬁnal model parameters
and coefﬁcients of variations are listed in Table 2.

4. Discussion
The pretreatment procedure for biological samples, especially tissues, should be well established
before beginning a pharmacokinetic study. In this
study, both plasma and tissue homogenates were
mixed with a 3-fold volume of acetonitrile to precipitate endogenous substances. Recovery is an
appropriate parameter to determine whether the
pre-treatment is sufﬁcient to quantify a substance.
The extraction recovery of PAN in organs in this
experiment ranged from 80 to 90% (data not shown).
The mean recovery (89%) in liver homogenate, as a
representative organ, was slightly better than that
(86%) in plasma, which indicates that the clean-up
procedure was sufﬁcient. Although the matrix effect
(82%) of liver homogenate was opposite to that
(85%) of plasma, the difference was negligible. The
endogenous substances in both plasma and organs
did not affect the quantiﬁcation of PAN.
In our previous study [14], the pharmacokinetic
behaviour of PAN was investigated following oral
administration of 5 mg/kg. The biphasic decay after

Fig. 3. Concentrationetime proﬁles of PAN for organs after oral administration of 200 mg/kg BPE (16 mg/kg as panduratin A) to rats (mean ± s.d.,
n ¼ 5).
Table 1. Areas under the PAN organ concentrationetime curve values for the heart, lung, liver, spleen, kidney, brain, gums, and skin after oral
administration of 200 mg/kg BPE (16 mg/kg as PAN) to rats. Values are means and standard deviations (n ¼ 5).
AUC24h (mg*h/g)

Skin

Lung

Heart

Gum

Liver

Spleen

Kidney

Brain

14.00 ± 2.51

7.28 ± 1.77

5.20 ± 1.49

4.58 ± 1.36

4.52 ± 2.65

3.31 ± 1.84

2.90 ± 0.71

2.09 ± 0.75
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Fig. 4. Panel A: a representative ﬁt of PAN plasma concentrationetime proﬁle derived using a two-compartment model including ﬁrst-order absorption and elimination, without (left) and with (right) of delay term, t (see Fig. 1, right); Panel B: Model-ﬁt of panduratin A in skin.
Table 2. Pharmacokinetic parameters of PAN in rat plasma and skin after oral administration of 200 mg/kg BPE (16 mg/kg as PAN).
Parameter

Ka (h1)

Kel (h1)

Vc (mL)

t (h)

Kcp (h1)

Kpc (h1)

Kcs (h1)

Ksc (h1)

Vs (mL)

mean
CV(%)

0.47
14.9

0.28
3.6

2.02
19.2

0.36
11.1

0.22
18.2

0.04
25.0

0.053
37.7

0.126
23.8

0.34
38.3

the plasma peak was similar to that observed in this
study. However, the terminal half-life (3.6 h) was
remarkably prolonged (2.4-fold; p < 0.01), and
clearance was decreased by 37% when PAN was
given as an ingredient in a BPE, probably indicating
that other substances (composing >80% of the
extract) may hinder PAN metabolism and/or
excretion. An increase of AUC normalized to the
dose (0.28e0.44 kg h/L) may also reﬂect this
possibility.
The change of clearance seemed to be much
smaller than that of half-life. Since pharmacokinetic
parameters are mostly calculated from the time
course of plasma concentrations, the change of
clearance is mainly dependent on the schedule of
blood sampling, dose, and quantiﬁcation sensitivity,
and the half-life can be much more variable
compared to the other parameters. PAN was previously monitored for up to 12 h due to early
disappearance from the systemic circulation, which
seems insufﬁcient for accurate measurement of the
half-life. Therefore, clearance is more reliable than
half-life when comparing pharmacokinetic changes
of PAN following oral administration of PAN and
BPE.
Systemic exposure to PAN increased in a dosedependent manner after oral administration of BPE
at doses of 50e200 mg/kg (Fig. 2B). We could predict
the tissue distribution of PAN down to 50 mg/kg
due to kinetic homogeneity. To the best of our
knowledge, this is the ﬁrst study to report tissue
concentrations of PAN, including in the skin and
gums. Although these two organs are not usually
examined, we were interested in the relationship
between the PAN concentrations therein and its

pharmacological activity [6e8,11]. Gum tissue samples were collected from the outer mandibular regions, and the PAN levels were similar to those in
the liver samples. PAN activity against LPS-induced
periodontitis is of interest [7,8], where few pharmacologically active substances have been derived
from natural products. PAN may also protect
against gingival inﬂammation.
There have been many previous reports of the
skin distribution of active substances following oral
administration, but fewer on the distribution in
major organs such as the liver, heart, lung, and
brain. Okawara et al. prepared b-cyclodextrin complexes of diosgenin, and assessed the reduction of
skin thickness in ovariectomized mice and distribution of diosgenin in the skin [17]. The complexes
improved the oral bioavailability of diosgenin by 8fold compared to diosgenin alone, and skin exposure was enhanced by 10-fold. In a rat study of the
intracellular lipids of the stratum corneum, 16% of
the tritium-labelled ceramide that was absorbed
orally remained in the dermis [18]. Substances
reaching the skin can improve its function. In
addition, exposure of the skin at the dermal
interstitium to doxycycline was studied using a
microdialysis technique, following daily oral
administration for 14 days in healthy volunteers
[19]. The AUC24h values of doxycycline in the skin
was 30% and 40% of that in the plasma on days 1
and 14, respectively. Considerable accumulation of
doxycycline in the skin was clearly demonstrated;
this accumulation may contribute to its efﬁcacy in
rosacea.
In this study, the PAN level was much higher in
skin than in the major organs; for example, it was
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Fig. 5. Panel A: Visual predictive check of the pharmacokinetic model of plasma (top) and skin PAN levels (bottom). The solid lines indicate the 50th
percentile, and the dashed lines indicate the 5th and 95th percentiles; Panel B: Simulated time courses of plasma (top) and skin (bottom) PAN levels
after oral administrations of 200 mg/kg of BPE (16 mg/kg as PAN) to rats. The solid and dashed lines are the mean and 90th percentile values,
respectively.

about two-fold higher than the concentration in
lung (the most exposed major tissue), perhaps
explaining the good skin-moisturizing and UV
irradiation-protective effects of PAN [10,11]. Therefore, we used model-dependent analysis to further
investigate skin exposure to PAN. The quality of the
model was assessed using a visual predictive check,
as shown in Fig. 5 (Panel A). Monte Carlo simulation
(1,000) was performed to obtain 90% conﬁdence
intervals (CIs). Few data points lay outside of the
CIs, indicating that the model predictions of plasma
and skin PAN were reliable.
Using the pharmacokinetic parameter data
derived by varying a single dose, stochastic simulation can predict plasma levels when different
doses are administered at various time points. Panel
B in Fig. 5 shows the results of simulations of plasma
and skin PAN levels after ﬁve BPE doses of 200 mg/
kg in rats. The time course of the skin PAN level can
be correlated with data on its moisturizing activity
or protective action, to enhance our understanding
of the relationship between PAN pharmacokinetics
and pharmacodynamics.
In summary, to the best of our knowledge, this
study is the ﬁrst to explore the time course of PAN
levels in rat plasma and major organs (including the
gums and skin) after oral administration of BPE. The
PAN level was highest in the skin, at twofold that in
the lungs; the level in the gums was 33% of that in
the skin. Our results help to explain the pharmacological activities of PAN in the skin and gums. The
pharmacokinetic model provided quantitative data
on plasma and skin PAN levels, which are of
fundamental importance when evaluating the efﬁcacy of PAN.
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